Call us at:
Equipped with state-of-the-art facilities and experienced immunology experts, Creative Biolabs is dedicated to providing high-quality GPLA genotyping services for our global clients.
The guinea pig MHC or guinea pig leucocyte antigen complex (GPLA) has been reported since 1973 and is classified into two classes. Class I antigens (BI, BL B3, or B4), these ubiquitous antigens correspond to mouse H2-D and H2-K antigens or to human HLA-A or HLA-B antigens. Class II and associated antigens (Ia), which have been defined as seven specificities (1, 2, 3, 4, 5, 6, 7). The GPLA antigens have a wide tissue distribution and are found on both lymphoid and nonlymphoid cells. In addition, class I and class II antigens are also present on some tumor cells including the L2C-N Leukemia. It was reported that, unlike mice or humans, most normally resting guinea pig T cells and most thymocytes have been reported to express Ia antigens. Class II antigens have also been described on several glandular epithelial cells, including guinea pig mammary gland cells.
With the advancement of genotyping approaches, GPLA genotyping has become accessible. Creative Biolabs has developed a dedicated NGS-based GPLA genotyping service to meet your program requirements. We are committed to providing more comprehensive and targeted accurate genotyping analysis results and facilitating scientific research. Our scientists and technicians are experienced in every step with high dedication to ensuring accurate outcomes.
Fig.1 Flow diagram of GPLA genotyping.
Creative Biolabs' scientists are dedicated to bringing together years of valuable experience to help our clients shorten the clinical study journey. We are committed to reducing the overall project development timeline for our clients. For further details, please don't hesitate to contact us and see how we can help you reach your clinical vision.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE